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of the blood volume is obtained without risk of such 
adverse reactions as intravascular coagulation. 
The study by Lai et al. is a controlled trial comparing 
DUF with a single large-volume paracentesis for the 
treatment of 12 cirrhotic patients with massive ascites. 
The results show that the average duration of treatment 
was 3.26 & 1.49 hr for DUF vs. 4.99 +- 1.45 hr for 
paracentesis and that the incidence of complications 
within 2 wk after treatment was significantly higher in 
patients treated with paracentesis. In fact, 50% of the 
patients treated with paracentesis suffered severe com- 
plications (e.g., coma, kidney failure, variceal bleeding), 
whereas patients treated with DUF had no complica- 
tions. Therefore the authors concluded that DUF of 
ascitic fluid is preferable to paracentesis because it takes 
less time and is free of adverse effects. 
Interpretation of the results of this paper requires 
careful observation. The number of subjects studied by 
Lai et al. was very small for a therapeutic trial conducted 
on patients with an already high spontaneous risk of 
complications. Moreover, large-volume paracentesis was 
performed at a very slow flow rate (1 L/hr) and was not 
associated with any kind of plasma reexpansion, in 
accord with a previous study by Kao et al. (6). This 
method of performing therapeutic paracentesis can be, 
in our opinion, criticized. Several trials in which large 
populations of cirrhotic patients were studied demon- 
strated that paracentesis can be performed without any 
risk, with a fluid rate of tap as high as 6 to 8 Lhr ,  and 
that complications are less frequent and almost always 
self-limited if paracentesis is combined with adequate 
plasma expansion obtained with human serum albumin 
or with synthetic colloids (7-11). On the contrary, it is 
well known that large-volume paracentesis performed 
without plasma expansion is associated with a high rate 
of hypovolemia-related adverse effects (11, 12). 
Therefore it is likely that the patients in this trial could 
have been treated in a shorter period of time and with 
substantially fewer and less severe side effects if para- 
centesis had been conducted in accord with the meth- 
odological procedures of other authors (9, 10). Never- 
theless, t o  have a method for treating refractory ascites 
that is completely free of any adverse effects is attractive 
to  most clinicians. It would be worthwhile to compare 
DUF with other treatments of refractory ascites per- 
formed using the best methods reported in the literature 
in a larger population. 
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PULMONARY DYSFUNCTION IN 
ADVANCED LIVER DISEASE 
Hourani JM, Bellamy PE, Tashkin DP, Batra P, 
Simmons MS. Pulmonary dysfunction in advanced liver 
disease: frequent occurrence of an abnormal diffusing 
capacity. Am J Med 1991;90:693-700. 
ABSTRACT 
PURPOSE: Abnormalities in pulmonary function 
have been reported in association with chronic liver 
disease of varied etiology. The aim of this study was to 
better define the frequency and nature of these abnor- 
malities in patients who were being evaluated for liver 
transplantation. 
PATIENTS AND METHODS: W e  performed a battery 
of pulmonary function tests and chest radiographs in 
116 consecutive patients (50 men, 66 women; aged 19 to 
70 years, mean 44.6 years) with severe advanced liver 
disease who were hospitalized spec%cally for evalu- 
ation for possible orthotopic liver transplantation and 
were able to perform technically satisfaotory tests. In 
17 patients, quantitative whole-body technetium-99m 
macroaggregated albumin perfusion scanning was also 
performed for assessment of possible right-to-left 
shunting through intrapulmonary vascular dilata- 
tions. 
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RESULTS: The most commonly affected test of lung 
function was the single-breath diffusing capacity for 
carbon monoxide (DL,,), which was abnormal in 48%, 
45%, and 71% of patients who never smoked, former 
smokers, and current smokers, respectively. Venti- 
latory restriction was noted in 25% of all patients, 
airflow obstruction (reduced ratio of forced expiratory 
volume in 1 second to forced vital capacity) in only 3%, 
and a widened alveolar-arterial oxygen gradient in 
45%. Diffusion impairment was accompanied by a 
restrictive defect in only 35% of the patients and by an 
abnormally widened alveolar-arterial oxygen gradient 
in 60%. When diffusion impairment was accompanied 
by an oxygenation defect, it was also associated with a 
significantly increased right-to-left shunt fraction 
(mean 24.9%) assessed from quantitative whole-body 
perfusion imaging. On the other hand, isolated dif- 
fusion impairment unaccompanied by significant hyp- 
oxemia (noted in approximately a third of the patients 
with a reduced DL,,) was not associated with evidence 
of significant intrapulmonary shunting (mean right- 
to-left shunt fraction 6.7%). 
CONCLUSIONS: Most patients with advanced liver 
disease have one or more types of abnormality in lung 
function, a reduced DL,, being the single most common 
functional defect. Mechanisms accounting for the ab- 
normality in gas transfer may include intrapulmonary 
vascular dilatations, diffuse interstitial lung disease, 
pulmonary vaso-occlusive disease, and/or ventilation- 
perfusion imbalance. 
COMMENTS 
Since 1884, liver disease has been known to be 
associated with pulmonary abnormalities (1). Many 
studies have reported that patients with severe liver 
disease usually have mild hypoxemia and abnormal 
diffusing capacity. Most of the literature on the subject 
is of limited value in that the number of subjects is 
usually small; the degree of liver disease is different from 
study to study, making comparisons difficult; and the 
results of pulmonary function testing and diffusing 
capacity (DLCO) are not available on all subjects. 
Although many mechanisms have been proposed, the 
cause or causes of pulmonary dysfunction in these 
patients remain unclear. 
One of the earlier proposed mechanisms for hypox- 
emia in patients with liver disease was decreased 
2,3DPG leading to abnormal oxygen dissociation curve 
(21. This has been proven not to be true and has fallen 
out of favor. Several studies have shown that a right- 
to-left shunt secondary to “pulmonary spider angioma” 
may be an important cause of abnormal DLCO and hyp- 
oxemia, especially in patients with peripheral spider an- 
gioma (3, 4). Dilated pulmonary vessels are predomi- 
nantly found in lower lobes. When a person assumes an 
upright position an increase is seen in blood flow to the 
lower lobes secondary to gravity. This causes more 
shunting and worsening hypoxemia (i.e., orthodeoxia). 
However, pulmonary spider angioma axe not present in 
all patients with pulmonary abnormalities. Another 
common cause of hypoxemia in patients with liver 
disease is ventilationlperfusion mismatch, which can be 
caused by atelectasis, pulmonary edema, pleural ef- 
fusion or an elevated diaphragm secondary to ascites or 
massive hepatomegaly. One of the factors that causes 
abnormal ventilation/perfusion is an increased closing 
capacity. Normally closing volume is smaller than func- 
tional residual capacity such that airways remain open 
at the end of normal exhalation. Some studies demon- 
strated that patients with liver disease have larger 
closing volume leading to earlier closure of airways (5, 
6). Other studies, however, found no change in closing 
capacity in patients with liver disease when compared 
with controls (7). 
The paper reviewed here studied 116 subjects who 
were being evaluated for liver transplantation. It is 
interesting that only 52 (45%) had an elevated A-a 0, 
gradient despite the fact that all these patients had 
severe liver disease. Although abnormal DLCO was the 
most common functional defect in these patients, it was 
present in only 60 (52%) of 116 patients. An elevated A-a 
0, gradient and abnormal DLCO was concomitantly 
present in 36 patients. Twenty-nine patients had a 
restrictive ventilatory defect (total lung capacity less 
than 80% of predicted). Not surprisingly, most of these 
patients had radiographic evidence of decreased lung 
volumes, ascites and/or pleural effusion and elevated A-a 
0, gradient and abnormal DLCO. Fourteen patients had 
an abnormal DLCO with a normal A-a 0, gradient. It is 
recognized that DLCO is the more sensitive mea- 
surement of pulmonary dysfunction than either lung 
volumes or hypoxemia. It is probable that abnormal 
diffusion capacity in these patients reflects an early 
change in pulmonary physiological processes. Of the 17 
patients who had whole-body technetium-99m macro- 
aggregated albumin perfusion scanning, only 6 had 
significantly elevated right-to-left shunting. All of these 
patients had concomitant hypoxemia and diffusion 
impairment. This is in agreement with other studies (8, 
9). Increased shunting is most likely caused by the 
presence of dilated pulmonary capillaries. It is unknown 
what factors in patients with severe liver disease cause 
the dilatation. 
This study reflects the difficulties inherent in exam- 
ining pulmonary dysfunction in cirrhotic patients, 
namely, different degrees of liver disease and multiple 
factors leading to hypoxemia in these patients. Although 
anecdotal cases exist of patients whose pulmonary 
dysfunction resolved with the improvement of liver 
disease, liver transplantation or both, it is not known 
whether all of processes leading to pulmonary dys- 
function are reversible with liver transplantation. It 
would have been interesting to know whether any 
changes in pulmonary dysfunction were seen after liver 
transplantation in these patients. 
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LOWER RATES OF POSTBIOPSY BLEEDING: 
NEEDLE VS. TECHNIQUE 
To the Editor: 
I read with interest Dr. Harold Conn’s review (1) of 
the article by McGill et al. (2) that reported the Mayo 
Clinic experience with hemorrhage after percutaneous 
liver biopsy using Tru-Cut and Jamshidi needles. In his 
review, Doctor Conn compares the Mayo group’s results 
with an Italian group’s experience with hemorrhage 
after percutaneous liver biopsy performed almost exclu- 
sively with the Menghini needle (3). Conn points out 
that the 0.04% incidence of hemorrhage in the Italian 
experience is significantly lower than the 0.4% incidence 
in the Mayo study (p c 0.0001). He also notes that the 
incidence of fatal hemorrhage was also significantly 
lower in the Italian group as compared with the Mayo 
group (p < 0,001). However, the percentage of patients 
in the Italian study with fatal hemorrhage is not 0.05% 
as reported by Conn but 0.005% (3 of 60,611). This 
corresponds to an even more significant decreased 
incidence of fatal hemorrhage in the Italian group 
compared with the Mayo experience (p < 0.0001). The 
corrected statistics give further support to the safety of 
the Menghini needle used by the Italian group compared 
with the Jamshidi and Tru-Cut needles used by the 
Mayo group. 
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Reply: 
The mathematical error noted by Dr. Schuller in my 
essay is indeed an error. Fatal hemorrhages occurred 
with the Menghini needle in 0.005%, not 0.05% as I had 
indicated. As he notes, this makes the risks of postbiopsy 
bleeding even smaller with the Menghini needle used by 
the Italian group than with the Jamshidi needle used by 
the Mayo group (p < 0.0001). 
This difference, however, cannot be attributed solely 
to differences in the needles themselves. Differences in 
the techniques used by the two groups and differences in 
the types of patients studied almost certainly con- 
tributed to the higher incidences of both postbiopsy 
bleeding and fatal postbiopsy hemorrhage in the Mayo 
series. These differences include the following: (a) a 
higher prevalence of neoplasia in the Mayo patients; (b) 
the biopsy protocol used by the Mayo physicians in 
patients suspected of having malignancy in whom 
multiple passes were performed - as many as 11 - until 
neoplastic tissue was obtained; (c)  the older age of the 
Mayo patients; (d) the greater prevalence of cancer in the 
